2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Wednesday, October 24, 2018

9:00AM-10:30AM: Abstract Number: 2913

A Draft Modified Core Domain Set for Patient-Reported Outcomes (PRO) in Patients with Idiopathic Inflammatory Myopathies (IIM): An Omeract Report

6W007 ACR Abstract: Patient Outcomes, Preferences, & Attitudes II: PROs (2910–2915)

9:00AM-10:30AM: Abstract Number: 2935

A Practical Classification of Systemic Sclerosis Using Subset and Autoantibodies for the Purpose of Early Risk Stratification

6W012 ACR Abstract: Systemic Sclerosis & Rel D/O III:Cohort Study, Biomarkers, & Response(2934–2939)

9:00AM-10:30AM: Abstract Number: 2908

Agreement between Ultrasound and Whole Body Magnetic Resonance Imaging Assessment of Joint Inflammation and Enthesitis in Rheumatoid Arthritis Patients

6W006 ACR Abstract: Imaging of Rheumatic Diseases II: Ultrasound (2904–2909)

9:00AM-10:30AM: Abstract Number: 2919

An Epidemic: Severe Lung Disease in Patients with Systemic Juvenile Idiopathic Arthritis, Risk Factors and Predictors

6W008 ACR Abstract: Pediatric Rheum–Clinical III: Assessment Tools & Biomarkers (2916–2921)

9:00AM-10:30AM: Abstract Number: 2937

Anti-Vinculin Antibodies in Systemic Sclerosis (SSc): A Potential Biomarker Linking Vascular and Gastrointestinal System Involvement in Two Phenotypically Distinctive SSc Groups

6W012 ACR Abstract: Systemic Sclerosis & Rel D/O III:Cohort Study, Biomarkers, & Response(2934–2939)

9:00AM-10:30AM: Abstract Number: 2902

Antibodies to PAD4 Drive Monocyte Activation and Differentiation into Osteoclast-like Cells

6W009 ACR Abstract: RA–Etiology & Pathogenesis II (2898–2903)

9:00AM-10:30AM: Abstract Number: 2915

Can Passively-Collected Phone Behavior Determine Rheumatic Disease Activity?

6W007 ACR Abstract: Patient Outcomes, Preferences, & Attitudes II: PROs (2910–2915)

9:00AM-10:30AM: Abstract Number: 2939

Clinical Features Associated with Severe Lower Bowel Involvement in Systemic Sclerosis

6W012 ACR Abstract: Systemic Sclerosis & Rel D/O III:Cohort Study, Biomarkers, & Response(2934–2939)

9:00AM-10:30AM: Abstract Number: 2907

Comparison of the Joints Ultrasonography in the Patients with Rheumatoid Arthritis Treated By Biological Agents and the Corresponding Synovial Histological Findings

6W006 ACR Abstract: Imaging of Rheumatic Diseases II: Ultrasound (2904–2909)

9:00AM-10:30AM: Abstract Number: 2940

Complementary Practices As Alternatives to Pain: Effectiveness of a Pain Management Program for Patients in an Orthopedic Clinic

6W016 ARHP Abstract: Interventions & Self-Management–ARHP III (2940–2945)

9:00AM-10:30AM: Abstract Number: 2920

Correlations of Type I Interferon Score and Interferon Induced Chemokines CXCL10 and CXCL9 with Cutaneous and Muscular Disease Activity in Juvenile Dermatomyositis

6W008 ACR Abstract: Pediatric Rheum–Clinical III: Assessment Tools & Biomarkers (2916–2921)

9:00AM-10:30AM: Abstract Number: 2945

Culturally Enhanced Pain Coping Skills Training for African Americans with Osteoarthritis

6W016 ARHP Abstract: Interventions & Self-Management–ARHP III (2940–2945)

9:00AM-10:30AM: Abstract Number: 2910

Development of a Rheumatoid Arthritis Global Outcome Measure to Enable Comparisons of Patient Experiences across Treatment Arms in Randomized Clinical Trials

6W007 ACR Abstract: Patient Outcomes, Preferences, & Attitudes II: PROs (2910–2915)

9:00AM-10:30AM: Abstract Number: 2909

Diagnostic and Prognostic Value of Ultrasound Compared with Plain Radiography in Knee Osteoarthritis

6W006 ACR Abstract: Imaging of Rheumatic Diseases II: Ultrasound (2904–2909)

9:00AM-10:30AM: Abstract Number: 2942

Dyadic Study of Partner Social Support for Physical Activity and Its Role in the Initiation and Maintenance of Increased Physical Activity Among Insufficiently Active People with Hip/Knee Osteoarthritis

6W016 ARHP Abstract: Interventions & Self-Management–ARHP III (2940–2945)

1
2
3
…
7
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.